{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Haroun-Izquierdo A"],"funding":["NCI NIH HHS"],"pagination":["e005577"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9628692"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(11)"],"pubmed_abstract":["<h4>Background</h4>Natural killer (NK) cells hold great promise as a source for allogeneic cell therapy against hematological malignancies, including acute myeloid leukemia (AML). Current treatments are hampered by variability in NK cell subset responses, a limitation which could be circumvented by specific expansion of highly potent single killer immunoglobulin-like receptor (KIR)<sup>+</sup>NKG2C<sup>+</sup> adaptive NK cells to maximize missing-self reactivity.<h4>Methods</h4>We developed a GMP-compliant protocol to expand adaptive NK cells from cryopreserved cells derived from select third-party superdonors, that is, donors harboring large adaptive NK cell subsets with desired KIR specificities at baseline. We studied the adaptive state of the cell product (ADAPT-NK) by flow cytometry "],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Adaptive single-KIR<sup>+</sup>NKG2C<sup>+</sup> NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia."],"pmcid":["PMC9628692"],"funding_grant_id":["P01 CA111412"],"pubmed_authors":["Miller JS","Blomberg P","Sohlberg E","Krokeide SZ","Berggren S","Valamehr B","Onfelt B","Kremer V","Ljunggren HG","Hammer Q","Bendzick L","Bjorklund A","Zhang B","Wikstrom K","Felices M","Momayyezi P","van Ooijen H","Kanaya M","Tjonnfjord G","Kveberg L","Li S","Vincenti M","Cichocki F","Wiiger MT","Haroun-Izquierdo A","Netskar H","Hoglund P","Malmberg KJ","Hoel HJ","Alici E"],"additional_accession":[]},"is_claimable":false,"name":"Adaptive single-KIR<sup>+</sup>NKG2C<sup>+</sup> NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia.","description":"<h4>Background</h4>Natural killer (NK) cells hold great promise as a source for allogeneic cell therapy against hematological malignancies, including acute myeloid leukemia (AML). Current treatments are hampered by variability in NK cell subset responses, a limitation which could be circumvented by specific expansion of highly potent single killer immunoglobulin-like receptor (KIR)<sup>+</sup>NKG2C<sup>+</sup> adaptive NK cells to maximize missing-self reactivity.<h4>Methods</h4>We developed a GMP-compliant protocol to expand adaptive NK cells from cryopreserved cells derived from select third-party superdonors, that is, donors harboring large adaptive NK cell subsets with desired KIR specificities at baseline. We studied the adaptive state of the cell product (ADAPT-NK) by flow cytometry ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2026-07-16T18:34:17.271Z","creation":"2026-07-11T03:08:39.349Z"},"accession":"S-EPMC9628692","cross_references":{"pubmed":["36319065"],"doi":["10.1136/jitc-2022-005577"]}}